What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Following a three-day selloff amid market turmoil attributed to the Trump administration’s sweeping tariffs announced last ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

Eli Lilly & Co.’s shares fell Monday morning after the Trump administration spiked a plan late last week to pay for obesity drugs for Medicare patients.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...

Copyright 2025 The Associated Press. All Rights Reserved. This image provided by Eli Lilly shows the company’s new ...